Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $13.2471.

A number of research firms have recently commented on VYGR. Wedbush cut their price objective on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 15th.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Privium Fund Management B.V. boosted its stake in Voyager Therapeutics by 16.6% during the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock worth $79,000 after buying an additional 3,596 shares during the last quarter. American Century Companies Inc. boosted its stake in Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after buying an additional 6,748 shares during the last quarter. CWM LLC boosted its stake in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after buying an additional 9,376 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Voyager Therapeutics by 10.0% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 121,098 shares of the company’s stock worth $377,000 after buying an additional 11,000 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $36,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Down 1.2%

Shares of VYGR stock opened at $4.22 on Thursday. The stock has a 50 day moving average of $3.58 and a 200 day moving average of $3.42. The stock has a market cap of $234.08 million, a P/E ratio of -2.28 and a beta of 0.90. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The company had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. On average, research analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.